Answers are grounded in this paper and cite their sources.
The central importance of tumour neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast cancer. This review gives a background to breast tumour neovascularization in in situ and invasive breast cancer, outlines the mechanisms by which this is achieved and discusses the influence of the microenvironment, focusing on hypoxia. The regulation of angiogenesis and the antivascular agents that are used in an antiangiogenic dosing schedule, both novel and conventional, are also summarized.
No takes yet. Share an insight, caveat, or question.
Fox et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: